Intervention Protocol

Anti-angiogenic therapy for lung cancer

  1. Nick Pavlakis1,*,
  2. Gavin Marx1,
  3. Shane White2,
  4. Christopher W Lee3,
  5. Mustafa Khasraw4

Editorial Group: Cochrane Lung Cancer Group

Published Online: 7 OCT 2009

Assessed as up-to-date: 3 JUL 2009

DOI: 10.1002/14651858.CD008047

How to Cite

Pavlakis N, Marx G, White S, Lee CW, Khasraw M. Anti-angiogenic therapy for lung cancer (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD008047. DOI: 10.1002/14651858.CD008047.

Author Information

  1. 1

    Royal North Shore Hospital, Department of Medical Oncology, St Leonards, NSW, Australia

  2. 2

    Austin Hospital, Oncology Unit, Victoria, Australia

  3. 3

    BC Cancer Agency - Fraser Valley Centre, Surrey, British Columbia, Canada

  4. 4

    Memorial Sloan-Kettering Cancer Center, Neuro-oncology, New York, USA

*Nick Pavlakis, Department of Medical Oncology, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW, 2065, Australia.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 7 OCT 2009




  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the benefits and harms of angiogenesis inhibitors in the treatment of lung cancer when given alone, following or in combination with chemotherapy or chemo-radiotherapy (in the case of locally advanced non-metastatic NSCLC or limited stage SCLC).